Inelastic adjustable-strap below-knee lymphedema compression wrap, coded to A6583 — the story so far

How to read this. This is a synthesis, not a new source of truth: every claim it cites carries the tag the candidate file gives it right now, copied not paraphrased, and every line quoted from a deck is quoted verbatim. See docs/narrative-spec.md.

The one-paragraph version

This is a below-knee compression wrap for adults with clinician-diagnosed lower-extremity lymphedema, aimed narrowly at the maintenance phase of complete decongestive therapy and at patients who cannot self-don a conventional flat-knit garment. It fastens with overlapping hook-and-loop straps instead of pulling on like a stocking, and each strap carries a printed window that lines up at a fixed tension — a purely mechanical gauge, no electronics — so a patient can reproduce roughly the same pressure at every donning without a fitter. The whole design was worked backwards from one Medicare code, A6583, whose descriptor names an adjustable-strap below-knee gradient wrap, and from one regulation, 21 CFR 880.5780, whose Class I paragraph is exempt from premarket notification. Both anchors are now partly verified and partly still open: the regulation's class and exemption are settled primary text, but whether this specific inelastic, lay-use device actually falls inside it is not; the benefit category and payment formula are settled primary text, but the code itself, its dollar figure, and its coverage breadth have never been read. A business case added since the candidate's Verifier passes has layered six further, entirely unchecked assumptions onto the file — about launch-calendar turnaround, financing, coinsurance-driven abandonment, incumbent licensing, a cash-pay channel, and a fallback premarket-clearance route. Underneath all of it sits a desirability question no connector can ever answer: whether the population defined by inability to self-don one garment can in fact self-apply a different one.

The story so far

The product exists because of an indication-scope lever, stated plainly in the candidate's own design rationale: the same strap-and-fabric assembly could be marketed under at least four different claims, and only the narrowest one — maintenance-phase compression for a documented lymphedema diagnosis, with no venous-return or blood-pooling language and no pressure-measurement claim about the indicator — keeps the device inside 21 CFR 880.5780(b), Class I and exempt from premarket notification. That regulation and its adjacent Class II paragraph are both now read off primary eCFR text: § 880.5780 exists and is titled "Medical support stocking" [claim 1: verified]; paragraph (b) is Class I and exempt from subpart E of part 807, and additionally exempt from part 820 CGMP except records and complaints [claim 2: verified]; paragraph (a) is Class II, also premarket-exempt but without the part 820 exemption [claim 3: verified]; and the two matching product codes, FQL and DWL, both map to 880.5780 [claim 4: verified] [claim 5: verified]. That is a real, favourable, primary-source-backed regulatory floor — and it is also where the file's single largest open question sits, raised by the same verified text rather than by an outside critic: both paragraphs identify a device "constructed of elastic material," while this candidate's mechanism is expressly inelastic short-stretch, and § 880.9 requires a premarket notification anyway for a device intended for lay use where the prior intended use was professional-only — which is exactly this candidate's self-application-without-a-fitter indication. Whether FDA reads this device into the generic type at all is unconfirmed, an FDA judgment no connector answers [claim 6: unconfirmed].

The reimbursement side follows the same shape: a real statutory anchor, and a code built to fit it that has never actually been read. 42 CFR 410.36(a)(4) lists "Gradient compression wraps with adjustable straps" as a distinct Medicare Part B lymphedema compression treatment item [claim 42: verified], and 42 CFR 414.1650(a) sets its payment basis at 80 percent of the lesser of the actual charge or a payment amount computed under the section's own methodology, for items furnished on or after January 1, 2024 [claim 43: verified]. But the HCPCS code the whole product was sized to, A6583, has never been checked against the CMS code set itself, because the local cache the connector needs is absent — nothing was searched [claim 8: unconfirmed], and the same is true of its garment comparators A6552/A6554 [claim 9: unconfirmed]. Whether the 2024-01-01 effective date the candidate assumes is correctly attributed to statute rather than to a search summary is also unread [claim 10: unconfirmed], as is the payment rule's actual dollar figure [claim 11: unconfirmed], the breadth of coverage across lymphedema diagnoses [claim 12: unconfirmed], and the PDAC coding-verification requirement and quantity/replacement limits that the file itself flags as the item most likely to gate first revenue [claim 14: unconfirmed]. One specific correction has already surfaced, and it did not come from this candidate's own Verifier pass: the A6583 descriptor, as read directly from the DME MAC's own coding-and-billing article, carries no "30-50 mmHg" qualifier at all, unlike the adjacent stocking codes that do — a real discrepancy with the candidate's stated "the descriptor match is by construction" claim, now itself on record as its own claim [claim 44: unconfirmed].

TAM, FTO/IP, moat, mechanism and capital intensity are, in the Verified Composite's own words, blank rather than low: no verified claim sits behind any of them. Of TAM's three decomposed components, none carries a number — Medicare claim volume for A6583 was never searched [claim 15: unconfirmed], net selling price is unverifiable by design [claim 16: unconfirmed], and the 10-20% obtainable-share assumption is doubly unconfirmable, both as a market claim and as an adoption claim in market-share clothing [claim 17: unconfirmed]; the often-cited 3-5 million prevalence figure is explicitly flagged in the file as not a TAM input and was not multiplied by anything [claim 18: unconfirmed]. FTO is unexamined rather than clear: no patent search has been run and no patent number is named anywhere in the file to look up [claim 19: unconfirmed], which leaves the product's only differentiator — the printed tension-calibration indicator — an asserted asset rather than a demonstrated one, and the moat claim inherits that same gap on its IP half while its channel half (would fitters stock a fifth brand) is unverifiable by design [claim 20: unconfirmed]. Mechanism and clinical risk rests on reasoning that no Stage 3 connector can check: sustained gradient compression is stated to be established maintenance therapy, so the material risk named is application over undiagnosed peripheral arterial disease, which the file says is worse on this device than on fitter-applied comparators precisely because the indication is self-application without a fitter [claim 21: unconfirmed]. Capital intensity and time-to-revenue is stated deliberately without a dollar or month figure and is explicitly conditional: if the exempt route does not hold, this is not a slower version of the same business, it is a different one [claim 22: unconfirmed].

The candidate's file also now carries six further assumptions, surfaced by a business case added 2026-09-03, sitting alongside the earlier deck-surfaced ones and equally unchecked: that the turnaround from establishment registration through PDAC coding-verification review and DMEPOS supplier (CMS-855S) enrolment is short enough to plan a launch calendar against [claim 51: unverified]; that the tooling, fitter-training, PDAC-verification and supplier-onboarding capital needed to reach a first billable claim is financeable within a launch-stage budget [claim 52: unverified]; that the 20 percent Medicare Part B coinsurance a beneficiary would owe does not, by itself, cause a material share of prescribed patients to decline or abandon the device before first dispensing [claim 53: unverified]; that at least one of the four named incumbents would pay a royalty or transfer price for a licensed strap tension-calibration indicator rather than build an equivalent one in-house [claim 54: unverified]; that a meaningful share of the indicated population or their caregivers would pay out of pocket above the coinsurance a covered A6583 pathway would leave them owing, sufficient to sustain a cash-pay channel independent of Medicare billing [claim 55: unverified]; and that a premarket-clearance route (510(k) or De Novo) exists and is fundable and timeable for this device even though no predicate has been identified for it under 880.5780 or any other regulation [claim 56: unverified]. Each is recorded exactly as its own tag says — a business-case assumption, never checked, so the Verifier can see it — and none of them narrows or resolves the regulatory-membership or reimbursement questions above; the last of the six is worth reading alongside claim 6, since it names the fallback path that would exist if the exempt-route reading fails, and that fallback is itself unverified rather than costed.

Underneath all of that sits the desirability question the rubric's nine factors were never built to score. The candidate's own indicated population is defined by an inability — cannot self-don a flat-knit garment — while the product's premise is a different self-application succeeding in that same population, and the file records this as having zero evidence on either side [claim 23: unconfirmed]. The domain dossier reaches toward that question from the flat-knit incumbent's side and comes back with the same population mismatch it warns against papering over: the strongest donning-difficulty and discontinuation evidence it located is upper-limb breast-cancer-related lymphedema, non-lymphedema venous disease, or non-US cohorts — never a US, lower-extremity, lymphedema-diagnosed population, which is exactly this candidate's target [dossier: lower-extremity-lymphedema-compression-therapy]. Two of the literature-scan claims already in this candidate's own file carry that same mismatch in their own citations: a Turkish upper-limb cohort and a Dutch general-hosiery cohort, both flagged by the Verifier as a jurisdiction mismatch rather than silently corrected [claim 49: unconfirmed] [claim 50: unconfirmed]. Whether certified fitters and DMEPOS suppliers — who, per the dossier, typically choose the product rather than the patient — would stock a fifth brand against four named incumbents is likewise unconfirmed [claim 24: unconfirmed], and clinician acceptance is not a marketing nicety but a precondition written directly into the intended_use: itself [claim 25: unconfirmed]. The dossier adds one gap the candidate file does not otherwise name: no publication located anywhere tests whether patients actually apply an adjustable wrap at sub-therapeutic tension at home, at what rate, or whether a printed elongation-window indicator changes that rate — the dossier calls this the single biggest evidence gap behind the candidate's core differentiator [dossier: lower-extremity-lymphedema-compression-therapy].

What's solid

• 21 CFR 880.5780 exists and is titled "Medical support stocking," checked against primary eCFR text [claim 1: verified]
• Paragraph (b) of that regulation is Class I, exempt from premarket notification under subpart E of part 807, and additionally exempt from part 820 CGMP except records and complaints [claim 2: verified]
• Paragraph (a) is Class II, also premarket-exempt, but without the part 820 exemption [claim 3: verified]
• FDA product code FQL maps to 21 CFR 880.5780 [claim 4: verified], and product code DWL does too [claim 5: verified]
• 42 CFR 410.36(a)(4) lists "gradient compression wraps with adjustable straps" as a distinct Medicare Part B lymphedema compression treatment item [claim 42: verified]
• 42 CFR 414.1650(a) sets the payment basis for these items at 80 percent of the lesser of the actual charge or a computed payment amount, effective for items furnished on or after January 1, 2024 [claim 43: verified]

What's still open

• Whether FDA reads an inelastic, lay-self-applied wrap into § 880.5780(b) at all, and whether § 880.9's lay-use provision requires a premarket notification anyway — the load-bearing regulatory question, not a connector gap [claim 6: unconfirmed]
• Whether the HCPCS A6583 descriptor this product was sized to actually exists as stated — never searched against primary CMS text [claim 8: unconfirmed] — and its comparator codes [claim 9: unconfirmed]
• Whether A6583's descriptor actually carries the "30-50 mmHg" qualifier the candidate assumes — the DME MAC's own coding article, read directly, shows no such qualifier [claim 44: unconfirmed]
• The statutory 2024-01-01 lymphedema benefit-category date [claim 10: unconfirmed], the payment formula's actual dollar figure [claim 11: unconfirmed], coverage breadth across lymphedema diagnoses [claim 12: unconfirmed], and PDAC coding-verification requirements with their quantity/replacement limits [claim 14: unconfirmed] [claim 45: unconfirmed]
• All three TAM components — Medicare claim volume [claim 15: unconfirmed], net selling price [claim 16: unconfirmed], and obtainable share against four incumbents [claim 17: unconfirmed] — plus a prevalence figure explicitly flagged as not a TAM input [claim 18: unconfirmed]
• FTO: no patent search performed, no number named [claim 19: unconfirmed]; the moat's IP half inherits that gap, and its channel half is unverifiable by design [claim 20: unconfirmed]
• Mechanism and clinical risk, including the arterial-insufficiency contraindication and ABI screening the file says mandatory labelling content requires — no Stage 3 connector answers a clinical-risk claim [claim 21: unconfirmed]
• Capital intensity and time-to-revenue, explicitly conditional on the regulatory membership question resolving first [claim 22: unconfirmed]
• The desirability crux: whether the population defined by inability to self-don a flat-knit garment can self-apply this wrap to a reproducible tension, unaided — zero evidence on either side [claim 23: unconfirmed]
• Whether certified fitters and DMEPOS suppliers would stock a fifth brand [claim 24: unconfirmed] and whether clinicians would accept a self-applied wrap as maintenance therapy, a precondition written into the intended_use: itself [claim 25: unconfirmed]
• Sixteen further deck-surfaced assumptions across all three lenses — flat-knit abandonment rates, sustained daily re-application, arterial-status documentation, perceived benefit, caregiver availability, gross margin after channel split, PDAC access for a new entrant, competitor-count bounds, incumbent response, non-Medicare payer parity, in-band gradient production, tension retention, human-factors-only validation, indicator calibration tolerance, laundering durability, and freedom to operate on the indicator itself — were never checked and remain unverified [claim 26: unverified] through [claim 41: unverified]
• Six further assumptions surfaced by the 2026-09-03 business case — launch-calendar turnaround, financing sufficiency for the path to first billable claim, whether the Part B coinsurance alone drives abandonment, whether an incumbent would license rather than copy the indicator, whether a cash-pay channel could sustain itself independent of Medicare billing, and whether a fallback premarket-clearance route exists and is fundable — were never checked and remain unverified [claim 51: unverified] through [claim 56: unverified]
• Five literature-scan findings stay unconfirmed by rule, however faithfully their text tracks the source abstract, because a Stage 0 scan carries no confidence tag [claim 46: unconfirmed], [claim 47: unconfirmed], [claim 48: unconfirmed]; two of the five carry a jurisdiction mismatch the Verifier flagged rather than silently corrected — a Turkish upper-limb cohort [claim 49: unconfirmed] and a Dutch general-hosiery cohort [claim 50: unconfirmed]
• No primary source exists for a US lower-extremity lymphedema prevalence figure — the commonly-cited 3-5 million range is aggregator-grade and a repeat dossier search for its origin came back empty — and no source anywhere measures what share of that population cannot self-don a flat-knit garment, the single most load-bearing epidemiological gap for this candidate [dossier: lower-extremity-lymphedema-compression-therapy]
• The care pathway — site of service, who fits and trains, and whether below-knee wraps are dispensed through the same channel as flat-knit garments — is essentially unresearched [dossier: lower-extremity-lymphedema-compression-therapy]
• No publication located anywhere tests whether patients actually apply an adjustable wrap at sub-therapeutic tension at home, at what rate, or whether a printed elongation-window indicator changes that rate — the single biggest evidence gap behind this candidate's own differentiator [dossier: lower-extremity-lymphedema-compression-therapy]

Where the three lenses agree — and where they don't

All three decks were rebuilt against the candidate as it now stands (source_updated: 2026-09-03) and none is STALE per check_decks.py. Read together, they converge on the same structural point from three different chairs: none of the money, market, or user questions has a single verified claim behind it anywhere in the file. One framing worth correcting rather than repeating: the desirability and feasibility decks' own opening lines describe the candidate as carrying "five verified claims," all regulatory — that was true of the file as it stood when those decks were drafted (2026-08-25), but the candidate's own Verified Composite now records seven verified claims, five regulatory [claim 1: verified] through [claim 5: verified] and two reimbursement — the benefit-category listing and payment-formula claims added in a later Verifier pass [claim 42: verified], [claim 43: verified]. Neither deck is flagged STALE by check_decks.py, and their load-bearing conditions below are unaffected by the correction, but a reader should not take either deck's own claim-count framing as current.

The desirability deck turns on the population the indication itself defines — people who cannot self-don one garment — and whether they can self-apply a different one to a reproducible tension, a condition the deck notes is invisible to every mechanism this repo has, since adoption returns unverifiable by design and the Gate Check would read the same whether the premise were true or false.

"whether a patient who cannot self-don a flat-knit garment can self-apply this multi-strap wrap to a reproducible target tension, unaided" — the load-bearing condition of the desirability deck (built 2026-08-25).

The viability deck turns on the reimbursement anchor the entire product was engineered backwards from — a code, a price, and a coverage stance, none of which has ever been read against primary CMS text, unlike the two regulation sections underneath it that already have been.

"what Medicare actually allows for A6583, and to whom" — the load-bearing condition of the viability deck (built 2026-08-25).

The feasibility deck turns on the one condition that changes what gets built rather than how well it is built: whether the verified, favourable exemption text actually reaches this specific device, given that the same primary text names "elastic material" against an expressly inelastic mechanism and names lay use as a case requiring notification against a self-application-without- a-fitter indication.

"whether FDA reads an inelastic adjustable-strap wrap, indicated for lay self-application without a fitter, into 21 CFR 880.5780(b) — or whether § 880.9 requires a premarket notification anyway" — the load-bearing condition of the feasibility deck (built 2026-08-25).

The load-bearing question

If FDA reads this inelastic wrap into the exempt paragraph of 880.5780 and Medicare's A6583 turns out to pay enough, on terms broad enough, to run a DMEPOS business on — does the population this device is indicated for, defined by its inability to self-don a flat-knit garment, actually succeed at self-applying a different multi-strap wrap to a reproducible target tension, unaided, at the rate the whole reimbursement and regulatory case, and now the business case built on top of it, has been assumed to serve?